NEOP..Neoprobe Device Featured in Breast Cancer Localization Procedure
Radioactive Seeds Used to Identify Non-Palpable Breast Lesions
businesswire
Press Release Source: Neoprobe Corporation On Monday May 17, 2010, 9:00 am EDT
DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative biomedical surgical oncology products, today announced that its gamma radiation detection system product line, which includes the neo2000® and neoprobe® GDS systems, was featured in a peer reviewed publication characterizing the emergence of the use of radioactive “seeds” to assist in the surgical excision of non-palpable breast lesions. The procedure, termed radioactive seed localization (RSL), was indicated by the researchers to be a promising alternative to the standard wire-localized breast biopsy procedure. The research, published in the American Journal of Surgery, was conducted by research teams at the Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; and the University of South Florida, Tampa, FL.
“The RSL research activity is a demonstration of the flexibility of the Neoprobe gamma detection platform,” said Dr. Richard Orahood, Neoprobe’s Medical Director. “The goal of Neoprobe is to work with researchers and clinicians to improve the treatment of the thousands of patients who are diagnosed with breast cancer annually. Neoprobe was at the forefront of the development of the intraoperative lymphatic mapping procedure for the staging of breast cancer. The development and implementation of innovative procedures like RSL may help improve the diagnosis and treatment of patients diagnosed with breast cancer.”
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com.
Contact:
Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
The Shoreham Group
Tim Ryan, 212-242-7777
